Follow
Jerry S Wolinsky, MD
Jerry S Wolinsky, MD
Emeritus Professor in Neurology, McGovern Medical School, UTHealth, The University of Texas Health
Verified email at uth.tmc.edu
Title
Cited by
Cited by
Year
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ...
Annals of neurology 69 (2), 292-302, 2011
98852011
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis
WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, ...
Annals of Neurology: Official Journal of the American Neurological …, 2001
87512001
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ...
Annals of Neurology: Official Journal of the American Neurological …, 2005
62522005
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
27912014
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis: results of a phase III multicenter, double‐blind, placebo‐controlled trial
KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak, ...
Neurology 45 (7), 1268-1276, 1995
23991995
Ocrelizumab versus placebo in primary progressive multiple sclerosis
X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ...
New England Journal of Medicine 376 (3), 209-220, 2017
14162017
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ...
New England Journal of Medicine 376 (3), 221-234, 2017
12902017
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ...
New England Journal of Medicine 365 (14), 1293-1303, 2011
10922011
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity …
G Comi, M Filippi, JS Wolinsky, ...
Annals of neurology 49 (3), 290-297, 2001
9982001
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak, ...
Neurology 50 (3), 701-708, 1998
6981998
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
C Confavreux, P O'Connor, G Comi, MS Freedman, AE Miller, TP Olsson, ...
The Lancet Neurology 13 (3), 247-256, 2014
5572014
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double‐blind, placebo‐controlled trial
JS Wolinsky, PA Narayana, P O'Connor, PK Coyle, C Ford, K Johnson, ...
Annals of neurology 61 (1), 14-24, 2007
4752007
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
F Fazekas, F Barkhof, M Filippi, RI Grossman, DKB Li, WI McDonald, ...
Neurology 53 (3), 448-448, 1999
3961999
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ...
The Lancet 387 (10023), 1075-1084, 2016
3722016
Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
PA Narayana, TJ Doyle, D Lai, JS Wolinsky
Annals of neurology 43 (1), 56-71, 1998
3661998
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines
JH Simon, D Li, A Traboulsee, PK Coyle, DL Arnold, F Barkhof, JA Frank, ...
American Journal of Neuroradiology 27 (2), 455-461, 2006
3612006
Isolation of metabolically active capillaries from rat brain1,2
GW Goldstein, JS Wolinsky, J Csejtey, I Diamond
Journal of neurochemistry 25 (5), 715-717, 1975
3591975
Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”
M Filippi, M Rovaris, MA Rocca, MP Sormani, JS Wolinsky, G Comi
Neurology 57 (4), 731-733, 2001
3442001
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
P Vermersch, A Czlonkowska, LME Grimaldi, C Confavreux, G Comi, ...
Multiple Sclerosis Journal 20 (6), 705-716, 2014
3342014
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
KP Johnson, BR Brooks, CC Ford, A Goodman, J Guarnaccia, RP Lisak, ...
Multiple Sclerosis Journal 6 (4), 255-266, 2000
3332000
The system can't perform the operation now. Try again later.
Articles 1–20